337 related articles for article (PubMed ID: 23144808)
1. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
2. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
Bice JS; Keim Y; Stasch JP; Baxter GF
Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
[TBL] [Abstract][Full Text] [Related]
3. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum.
Estancial CS; Rodrigues RL; De Nucci G; Antunes E; Mónica FZ
BJU Int; 2015 Oct; 116(4):657-64. PubMed ID: 25715977
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
6. Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase.
Roger S; Paysant J; Badier-Commander C; Cordi A; Verbeuren TJ; Félétou M
Vascul Pharmacol; 2010; 53(5-6):281-7. PubMed ID: 20933607
[TBL] [Abstract][Full Text] [Related]
7. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.
Wang WZ; Jones AW; Wang M; Durante W; Korthuis RJ
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H521-32. PubMed ID: 23771693
[TBL] [Abstract][Full Text] [Related]
8. The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis.
Baldissera L; Squebola-Cola DM; Calixto MC; Lima-Barbosa AP; Rennó AL; Anhê GF; Condino-Neto A; De Nucci G; Antunes E
Pulm Pharmacol Ther; 2016 Dec; 41():86-95. PubMed ID: 27816773
[TBL] [Abstract][Full Text] [Related]
9. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
[TBL] [Abstract][Full Text] [Related]
10. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation.
Tsai EJ; Liu Y; Koitabashi N; Bedja D; Danner T; Jasmin JF; Lisanti MP; Friebe A; Takimoto E; Kass DA
Circ Res; 2012 Jan; 110(2):295-303. PubMed ID: 22095726
[TBL] [Abstract][Full Text] [Related]
11. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP
Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020
[TBL] [Abstract][Full Text] [Related]
13. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
14. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.
Roger S; Badier-Commander C; Paysant J; Cordi A; Verbeuren TJ; Félétou M
Br J Pharmacol; 2010 Nov; 161(5):1044-58. PubMed ID: 20977455
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
[TBL] [Abstract][Full Text] [Related]
16. Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production.
Monteiro PF; Morganti RP; Delbin MA; Calixto MC; Lopes-Pires ME; Marcondes S; Zanesco A; Antunes E
Cardiovasc Diabetol; 2012 Jan; 11():5. PubMed ID: 22248260
[TBL] [Abstract][Full Text] [Related]
17. Soluble guanylate cyclase modulators blunt hyperoxia effects on calcium responses of developing human airway smooth muscle.
Britt RD; Thompson MA; Kuipers I; Stewart A; Vogel ER; Thu J; Martin RJ; Pabelick CM; Prakash YS
Am J Physiol Lung Cell Mol Physiol; 2015 Sep; 309(6):L537-42. PubMed ID: 26254425
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells.
Hoffmann LS; Schmidt PM; Keim Y; Hoffmann C; Schmidt HH; Stasch JP
PLoS One; 2011; 6(8):e23596. PubMed ID: 21858179
[TBL] [Abstract][Full Text] [Related]
19. Effects of hydrogen peroxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries.
Tawa M; Shimosato T; Iwasaki H; Imamura T; Okamura T
Free Radic Res; 2015; 49(12):1479-87. PubMed ID: 26334090
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle.
Báu FR; Mónica FZ; Priviero FB; Baldissera L; de Nucci G; Antunes E
Eur J Pharmacol; 2010 Jul; 637(1-3):171-7. PubMed ID: 20399768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
